SequelSEC

NovoCure Ltd NVCR

Surgical & Medical Instruments & Apparatus · CIK 0001645113 · Fiscal year ends 1231

Revenue
$655.35M
Fiscal year ended 2025-12-31
Operating income
-$153.80M
Fiscal year ended 2025-12-31
Free cash flow
-$75.68M
Fiscal year ended 2025-12-31

NovoCure Ltd (NVCR) reported revenue of $655.35M and net income of -$136.23M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NovoCure Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NovoCure Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$655.35M$605.22M$509.34M$537.84M$535.03M$494.37M$351.32M$248.07M$177.03M$82.89M
Cost of revenue$166.88M$137.18M$128.28M$114.87M$114.88M$106.50M$88.61M$80.05M$55.61MUnavailable
Gross profit$488.47M$468.04M$381.06M$422.97M$420.15M$387.86M$262.71M$168.02M$121.42MUnavailable
Operating income-$153.80M-$170.50M-$232.87M-$89.52M-$44.33M$30.40M-$914.00K-$33.67M-$39.33M-$115.32M
Net income-$136.23M-$168.63M-$207.04M-$92.53M-$58.35M$19.81M-$7.23M-$63.56M-$61.66M-$131.84M
Research & development$224.54M$209.64M$223.06M$206.08M$201.30M$132.01M$79.00M$50.57M$38.10M$41.47M
Weighted-average diluted sharesshares 111.47Mshares 107.83Mshares 106.39Mshares 104.66Mshares 103.43Mshares 108.88Mshares 97.24Mshares 91.83MUnavailableUnavailable
Pretax income-$136.25M-$131.16M-$191.74M-$81.85M-$52.08M$18.10M-$8.82M-$45.94M-$48.50M-$121.46M
Income tax expense-$23.00K$37.46M$15.30M$10.69M$6.28M-$1.71M-$1.59M$17.62M$13.16M$10.38M
Diluted EPS$-1.22$-1.56$-1.95$-0.88$-0.56$0.18$-0.07$-0.69UnavailableUnavailable
Selling, general & administrative$417.73M$428.89M$390.87M$306.41M$263.18M$225.45M$184.62M$151.12M$122.64M$110.46M
General & administrative$177.67M$189.83M$164.06M$132.75M$126.13M$107.44M$87.95M$73.46M$59.11M$51.01M
Selling & marketing$240.06M$239.06M$226.81M$173.66M$137.06M$118.02M$96.68M$77.66M$63.53M$59.45M

Balance

NovoCure Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$93.55M$163.77M$240.82M$115.33M$208.80M$234.67M$177.32M$140.62M$78.59M$99.78M
Total assets$804.33M$1.24B$1.15B$1.19B$1.14B$1.05B$479.45M$339.79M$265.30M$282.08M
Current assets$646.73M$1.11B$1.03B$1.11B$1.07B$999.44M$439.95M$321.37M$245.13M$261.87M
Total liabilities$463.86M$880.60M$783.63M$750.48M$729.00M$575.46M$261.66M$227.53M$151.73M$139.74M
Current liabilities$223.23M$756.39M$179.12M$158.78M$142.60M$113.61M$86.31M$64.56M$50.20M$36.88M
Total equity incl. NCI$340.47M$360.18M$362.50M$441.17M$410.49M$476.53M$217.79M$112.26M$113.56M$142.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$41.11M$35.09M$38.15M$29.38M$24.43M$27.42M$23.70M$22.56M$22.02M$25.55M
Accounts receivable$89.44M$74.23M$61.22M$86.26M$93.57M$96.70M$58.86M$36.52M$29.57M$6.34M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$195.05M$97.30M$568.82M$565.51M$562.22M$429.90M$149.42M$149.27M$97.34M$96.23M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

NovoCure Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$49.03M-$26.37M-$73.34M$30.79M$82.76M$99.15M$26.62M-$1.86M-$33.13M-$107.59M
Capital expenditures$26.65M$42.86M$27.09M$21.36M$24.17M$14.97M$10.48M$6.71M$7.37M$5.67M
Investing cash flow$437.28M-$140.24M$184.15M-$139.96M-$144.83M-$472.85M-$51.67M-$5.49M$8.63M$13.00M
Financing cash flow-$451.34M$90.32M$15.79M$15.49M$25.70M$440.21M$61.68M$69.37M$5.17M$75.12M
Net change in cash-$62.70M-$76.47M$126.73M-$93.78M-$36.56M$66.76M$36.66M$62.04M-$19.33M-$19.64M
Stock-based compensation$104.83M$160.04M$115.61M$106.96M$94.90M$75.72M$52.42M$39.85M$27.12M$22.14M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$14.65M$11.24M$10.97M$10.62M$10.25M$9.15M$8.46M$9.01M$7.68M$5.65M

Derived

NovoCure Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$75.68M-$69.22M-$100.43M$9.43M$58.59M$84.18M$16.14M-$8.58M-$40.50M-$113.26M
Gross margin74.5%77.3%74.8%78.6%78.5%78.5%74.8%67.7%68.6%44.2%
Operating margin-23.5%-28.2%-45.7%-16.6%-8.3%6.1%-0.3%-13.6%-22.2%-139.1%
FCF margin-11.5%-11.4%-19.7%1.8%11.0%17.0%4.6%-3.5%-22.9%-136.6%
SBC / revenue16.0%26.4%22.7%19.9%17.7%15.3%14.9%16.1%15.3%26.7%
Current ratio2.90x1.46x5.78x7.00x7.53x8.80x5.10x4.98x4.88x7.10x
Revenue YoY growth8.3%18.8%-5.3%0.5%8.2%40.7%41.6%40.1%113.6%Unavailable
Net margin-20.8%-27.9%-40.6%-17.2%-10.9%4.0%-2.1%-25.6%-34.8%-159.1%
R&D / revenue34.3%34.6%43.8%38.3%37.6%26.7%22.5%20.4%21.5%50.0%
CapEx / revenue4.1%7.1%5.3%4.0%4.5%3.0%3.0%2.7%4.2%6.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable-9.4%UnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NVCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-24View SEC filing
10-Q · Filed 2025-04-24View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2016-12-31

Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.